LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Cempra, Inc. (“Cempra” or the “Company”) (Nasdaq: CEMP) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.
The investigation focuses on the November 2, 2016 announcement by the U.S. Food and Drug Administration, which posted a preliminary review on its website of Cempra’s drug, solithromycin, highlighting a significant safety signal for hepatotoxicity. When this information was announced to the public, shares of Cempra dropped in value.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.